What is the current market valuation of the Transient Ischemic Attack market?

The market valuation of the Transient Ischemic Attack market was 137.57 USD Million in 2024. Read More

What is the projected market size for the Transient Ischemic Attack market by 2035?

The projected market size for the Transient Ischemic Attack market is 252.62 USD Million by 2035. Read More

What is the expected CAGR for the Transient Ischemic Attack market during the forecast period 2025 - 2035?

The expected CAGR for the Transient Ischemic Attack market during the forecast period 2025 - 2035 is 5.64%. Read More

Which companies are the key players in the Transient Ischemic Attack market?

Key players in the Transient Ischemic Attack market include Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Sanofi, Pfizer, Roche, Novartis, Johnson & Johnson, and Merck & Co. Read More

What are the main types of Transient Ischemic Attacks and their market valuations?

The main types of Transient Ischemic Attacks include Atherosclerotic (50.0 - 95.0 USD Million), Non-Atherosclerotic (30.0 - 56.0 USD Million), and Embolic (57.57 - 101.62 USD Million). Read More

What symptoms are associated with Transient Ischemic Attacks and their market values?

Symptoms associated with Transient Ischemic Attacks include Sudden Weakness (30.0 - 56.0 USD Million), Speech Difficulties (25.0 - 48.0 USD Million), and Dizziness (27.57 - 52.0 USD Million). Read More

What are the primary risk factors for Transient Ischemic Attacks and their market valuations?

Primary risk factors for Transient Ischemic Attacks include Hypertension (30.0 - 55.0 USD Million), Diabetes (25.0 - 45.0 USD Million), and Obesity (47.57 - 82.62 USD Million). Read More

What diagnostic methods are utilized for Transient Ischemic Attacks and their market values?

Diagnostic methods for Transient Ischemic Attacks include MRI (40.0 - 75.0 USD Million), CT Scan (30.0 - 55.0 USD Million), and Blood Tests (42.57 - 77.62 USD Million). Read More

What treatment options are available for Transient Ischemic Attacks and their market valuations?

Treatment options for Transient Ischemic Attacks include Antiplatelet Therapy (40.0 - 75.0 USD Million), Anticoagulants (30.0 - 55.0 USD Million), and Surgery (42.57 - 72.62 USD Million). Read More

How does the market for Transient Ischemic Attacks compare across different segments?

The market for Transient Ischemic Attacks shows varied valuations across segments, with Atherosclerotic types leading, followed by Embolic and Non-Atherosclerotic types. Read More

Transient Ischemic Attack Market

ID: MRFR/Pharma/3590-CR

226 Pages

Vikita Thakur

Last Updated: May 15, 2026

Transient Ischemic Attack Market Research Report Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2035

Transient Ischemic Attack Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.64%

2024 Market Size$ 137.57 Million

2025 Market Size$ 146.9 Million

2035 Market Size$ 252.62 Million

Key Players

Boehringer Ingelheim

AstraZeneca

Bristol-Myers Squibb

Sanofi

Pfizer

Novartis

Trends

Technological Advancements in Diagnostics
Increased Focus on Preventive Care
Integration of Telehealth Solutions

Opportunities

Aging Population
Rising Incidence of Stroke
Market Trends and Projections

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Transient Ischemic Attack (USD Million)
  1. 4.1.1 Non-Atherosclerotic
  2. 4.1.2 Atherosclerotic
  3. 4.1.3 Embolic
2. 4.2 Healthcare, BY Symptoms (USD Million)
  1. 4.2.1 Sudden Weakness
  2. 4.2.2 Speech Difficulties
  3. 4.2.3 Vision Problems
  4. 4.2.4 Dizziness
  5. 4.2.5 Confusion
3. 4.3 Healthcare, BY Risk Factors (USD Million)
  1. 4.3.1 Hypertension
  2. 4.3.2 Diabetes
  3. 4.3.3 High Cholesterol
  4. 4.3.4 Smoking
  5. 4.3.5 Obesity
4. 4.4 Healthcare, BY Diagnosis Method (USD Million)
  1. 4.4.1 CT Scan
  2. 4.4.2 MRI
  3. 4.4.3 Ultrasound
  4. 4.4.4 Blood Tests
5. 4.5 Healthcare, BY Treatment Options (USD Million)
  1. 4.5.1 Antiplatelet Therapy
  2. 4.5.2 Anticoagulants
  3. 4.5.3 Lifestyle Modifications
  4. 4.5.4 Surgery
6. 4.6 Healthcare, BY Region (USD Million)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Boehringer Ingelheim (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Roche (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck & Co. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
4. 6.4 US MARKET ANALYSIS BY SYMPTOMS
5. 6.5 US MARKET ANALYSIS BY RISK FACTORS
6. 6.6 US MARKET ANALYSIS BY DIAGNOSIS METHOD
7. 6.7 US MARKET ANALYSIS BY TREATMENT OPTIONS
8. 6.8 CANADA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
9. 6.9 CANADA MARKET ANALYSIS BY SYMPTOMS
10. 6.10 CANADA MARKET ANALYSIS BY RISK FACTORS
11. 6.11 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD
12. 6.12 CANADA MARKET ANALYSIS BY TREATMENT OPTIONS
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
15. 6.15 GERMANY MARKET ANALYSIS BY SYMPTOMS
16. 6.16 GERMANY MARKET ANALYSIS BY RISK FACTORS
17. 6.17 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD
18. 6.18 GERMANY MARKET ANALYSIS BY TREATMENT OPTIONS
19. 6.19 UK MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
20. 6.20 UK MARKET ANALYSIS BY SYMPTOMS
21. 6.21 UK MARKET ANALYSIS BY RISK FACTORS
22. 6.22 UK MARKET ANALYSIS BY DIAGNOSIS METHOD
23. 6.23 UK MARKET ANALYSIS BY TREATMENT OPTIONS
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
25. 6.25 FRANCE MARKET ANALYSIS BY SYMPTOMS
26. 6.26 FRANCE MARKET ANALYSIS BY RISK FACTORS
27. 6.27 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD
28. 6.28 FRANCE MARKET ANALYSIS BY TREATMENT OPTIONS
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
30. 6.30 RUSSIA MARKET ANALYSIS BY SYMPTOMS
31. 6.31 RUSSIA MARKET ANALYSIS BY RISK FACTORS
32. 6.32 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
33. 6.33 RUSSIA MARKET ANALYSIS BY TREATMENT OPTIONS
34. 6.34 ITALY MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
35. 6.35 ITALY MARKET ANALYSIS BY SYMPTOMS
36. 6.36 ITALY MARKET ANALYSIS BY RISK FACTORS
37. 6.37 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD
38. 6.38 ITALY MARKET ANALYSIS BY TREATMENT OPTIONS
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
40. 6.40 SPAIN MARKET ANALYSIS BY SYMPTOMS
41. 6.41 SPAIN MARKET ANALYSIS BY RISK FACTORS
42. 6.42 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD
43. 6.43 SPAIN MARKET ANALYSIS BY TREATMENT OPTIONS
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY SYMPTOMS
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY RISK FACTORS
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY TREATMENT OPTIONS
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
51. 6.51 CHINA MARKET ANALYSIS BY SYMPTOMS
52. 6.52 CHINA MARKET ANALYSIS BY RISK FACTORS
53. 6.53 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD
54. 6.54 CHINA MARKET ANALYSIS BY TREATMENT OPTIONS
55. 6.55 INDIA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
56. 6.56 INDIA MARKET ANALYSIS BY SYMPTOMS
57. 6.57 INDIA MARKET ANALYSIS BY RISK FACTORS
58. 6.58 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD
59. 6.59 INDIA MARKET ANALYSIS BY TREATMENT OPTIONS
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
61. 6.61 JAPAN MARKET ANALYSIS BY SYMPTOMS
62. 6.62 JAPAN MARKET ANALYSIS BY RISK FACTORS
63. 6.63 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD
64. 6.64 JAPAN MARKET ANALYSIS BY TREATMENT OPTIONS
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY SYMPTOMS
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY RISK FACTORS
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY TREATMENT OPTIONS
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
71. 6.71 MALAYSIA MARKET ANALYSIS BY SYMPTOMS
72. 6.72 MALAYSIA MARKET ANALYSIS BY RISK FACTORS
73. 6.73 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
74. 6.74 MALAYSIA MARKET ANALYSIS BY TREATMENT OPTIONS
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
76. 6.76 THAILAND MARKET ANALYSIS BY SYMPTOMS
77. 6.77 THAILAND MARKET ANALYSIS BY RISK FACTORS
78. 6.78 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD
79. 6.79 THAILAND MARKET ANALYSIS BY TREATMENT OPTIONS
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
81. 6.81 INDONESIA MARKET ANALYSIS BY SYMPTOMS
82. 6.82 INDONESIA MARKET ANALYSIS BY RISK FACTORS
83. 6.83 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD
84. 6.84 INDONESIA MARKET ANALYSIS BY TREATMENT OPTIONS
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
86. 6.86 REST OF APAC MARKET ANALYSIS BY SYMPTOMS
87. 6.87 REST OF APAC MARKET ANALYSIS BY RISK FACTORS
88. 6.88 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD
89. 6.89 REST OF APAC MARKET ANALYSIS BY TREATMENT OPTIONS
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
92. 6.92 BRAZIL MARKET ANALYSIS BY SYMPTOMS
93. 6.93 BRAZIL MARKET ANALYSIS BY RISK FACTORS
94. 6.94 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD
95. 6.95 BRAZIL MARKET ANALYSIS BY TREATMENT OPTIONS
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
97. 6.97 MEXICO MARKET ANALYSIS BY SYMPTOMS
98. 6.98 MEXICO MARKET ANALYSIS BY RISK FACTORS
99. 6.99 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD
100. 6.100 MEXICO MARKET ANALYSIS BY TREATMENT OPTIONS
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
102. 6.102 ARGENTINA MARKET ANALYSIS BY SYMPTOMS
103. 6.103 ARGENTINA MARKET ANALYSIS BY RISK FACTORS
104. 6.104 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD
105. 6.105 ARGENTINA MARKET ANALYSIS BY TREATMENT OPTIONS
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY SYMPTOMS
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY RISK FACTORS
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT OPTIONS
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY SYMPTOMS
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY RISK FACTORS
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT OPTIONS
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY SYMPTOMS
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY RISK FACTORS
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT OPTIONS
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE OF TRANSIENT ISCHEMIC ATTACK
123. 6.123 REST OF MEA MARKET ANALYSIS BY SYMPTOMS
124. 6.124 REST OF MEA MARKET ANALYSIS BY RISK FACTORS
125. 6.125 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD
126. 6.126 REST OF MEA MARKET ANALYSIS BY TREATMENT OPTIONS
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2024 TO 2035 (USD Million)
135. 6.135 HEALTHCARE, BY SYMPTOMS, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY SYMPTOMS, 2024 TO 2035 (USD Million)
137. 6.137 HEALTHCARE, BY RISK FACTORS, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY RISK FACTORS, 2024 TO 2035 (USD Million)
139. 6.139 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
141. 6.141 HEALTHCARE, BY TREATMENT OPTIONS, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY TREATMENT OPTIONS, 2024 TO 2035 (USD Million)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.2.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.2.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.2.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.2.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.3.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.3.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.3.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.3.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.4.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.4.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.4.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.4.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.5.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.5.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.5.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.5.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.6.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.6.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.6.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.6.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.7.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.7.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.7.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.7.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.8.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.8.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.8.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.8.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.9.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.9.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.9.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.9.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.10.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.10.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.10.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.10.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.11.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.11.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.11.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.11.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.12.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.12.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.12.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.12.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.13.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.13.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.13.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.13.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.14.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.14.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.14.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.14.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.15.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.15.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.15.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.15.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.16.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.16.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.16.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.16.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.17.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.17.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.17.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.17.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.18.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.18.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.18.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.18.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.19.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.19.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.19.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.19.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.20.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.20.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.20.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.20.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.21.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.21.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.21.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.21.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.22.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.22.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.22.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.22.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.23.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.23.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.23.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.23.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.24.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.24.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.24.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.24.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.25.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.25.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.25.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.25.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.26.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.26.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.26.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.26.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.27.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.27.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.27.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.27.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.28.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.28.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.28.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.28.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.29.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.29.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.29.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.29.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF TRANSIENT ISCHEMIC ATTACK, 2025-2035 (USD Million)
  2. 7.30.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.30.3 BY RISK FACTORS, 2025-2035 (USD Million)
  4. 7.30.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.30.5 BY TREATMENT OPTIONS, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Transient Ischemic Attack Market Segmentation

Transient Ischemic Attack Market By Type of Transient Ischemic Attack (USD Million, 2025-2035)

Non-Atherosclerotic
Atherosclerotic
Embolic

Transient Ischemic Attack Market By Symptoms (USD Million, 2025-2035)

Sudden Weakness
Speech Difficulties
Vision Problems
Dizziness
Confusion

Transient Ischemic Attack Market By Risk Factors (USD Million, 2025-2035)

Hypertension
Diabetes
High Cholesterol
Smoking
Obesity

Transient Ischemic Attack Market By Diagnosis Method (USD Million, 2025-2035)

CT Scan
MRI
Ultrasound
Blood Tests

Transient Ischemic Attack Market By Treatment Options (USD Million, 2025-2035)

Antiplatelet Therapy
Anticoagulants
Lifestyle Modifications
Surgery

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”